Paper42872032PubMed
Metabolic dysfunction-associated steatotic liver disease (MASLD) versus metabolic dysfunction and alcohol-associated steatotic liver disease (Met-ALD), do the differences matter in clinical practice?
Byrne CD. Hepatobiliary Surg Nutr, 2026.
Cite this record
ConductScience Library. Metabolic dysfunction-associated steatotic liver disease (MASLD) versus metabolic dysfunction and alcohol-associated steatotic liver disease (Met-ALD), do the differences matter in clinical practice? Papers, record 42872032. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42872032
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Metabolic dysfunction-associated steatotic liver disease (MASLD) versus metabolic dysfunction and alcohol-associated steatotic liver disease (Met-ALD), do the differences matter in clinical practice?
- Journal
- Hepatobiliary Surg Nutr
- Year
- 2026
- Publication types
- Editorial, Comment
- Revised in PubMed
- 2026-10-15
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 40953570 | Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. | https://conductscience.org/library/papers/40953570 |
Source PubMed
References16
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39548715 | Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD: A UK Biobank Study. | Liver Int | 2025 | https://conductscience.org/library/papers/39548715 | PubMed |
| 2 | 20223875 | Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. | BMJ | 2010 | https://conductscience.org/library/papers/20223875 | PubMed |
| 3 | 25920090 | NAFLD: a multisystem disease. | J Hepatol | 2015 | https://conductscience.org/library/papers/25920090 | PubMed |
| 4 | 37363821 | A multisociety Delphi consensus statement on new fatty liver disease nomenclature. | Hepatology | 2023 | https://conductscience.org/library/papers/37363821 | PubMed |
| 5 | 40316227 | Longitudinal Clinical Outcomes and Mortality from Steatotic Liver Disease: A Meta-Analysis. | Am J Med | 2025 | https://conductscience.org/library/papers/40316227 | PubMed |
| 6 | 27543837 | The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. | Hepatology | 2016 | https://conductscience.org/library/papers/27543837 | PubMed |
| 7 | 40802944 | Metabolic Dysfunction-Associated Steatotic Liver Disease. | N Engl J Med | 2025 | https://conductscience.org/library/papers/40802944 | PubMed |
| 8 | 30180285 | Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States. | Hepatology | 2019 | https://conductscience.org/library/papers/30180285 | PubMed |
| 9 | 38228377 | MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. | Gut | 2024 | https://conductscience.org/library/papers/38228377 | PubMed |
| 10 | 40414560 | Impact of metabolic dysfunction severity in steatotic liver disease and its interaction with liver fibrosis on all-cause mortality and multiple hepatic and extra-hepatic outcomes. | Metabolism | 2025 | https://conductscience.org/library/papers/40414560 | PubMed |
| 11 | 41652552 | Association between steatotic liver disease (MASLD, met-ALD, and ALD) with preserved ratio impaired spirometry: a population-based study. | BMC Pulm Med | 2026 | https://conductscience.org/library/papers/41652552 | PubMed |
| 12 | 20223873 | Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. | BMJ | 2010 | https://conductscience.org/library/papers/20223873 | PubMed |
| 13 | 40953570 | Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. | Lancet Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/40953570 | PubMed |
| 14 | 36063967 | Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. | J Hepatol | 2023 | https://conductscience.org/library/papers/36063967 | PubMed |
| 15 | 41368474 | Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes? | Curr Hepatol Rep | 2025 | https://conductscience.org/library/papers/41368474 | PubMed |
| 16 | 19766548 | Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. | Dig Liver Dis | 2010 | https://conductscience.org/library/papers/19766548 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42872032
GET https://conductscience.org/api/papers/v1/42872032/authors